Zimmer Biomet Holdings Announces $0.24 Quarterly Dividend, Reinforcing Commitment to Innovation and Care

Zimmer Biomet Expands Commitment to Innovation and Patient Care with Quarterly Dividend Announcement

Zimmer Biomet Holdings, Inc., a leader in the global medical technology sphere, reaffirms its dedication to enhancing patient care and innovation by announcing a quarterly cash dividend of $0.24 per share for the first quarter of 2026. This initiative demonstrates the company's commitment to returning value to its shareholders while simultaneously investing in transformative technologies that advance orthopedic solutions worldwide. Shareholders can expect the dividend payment on or about April 30, 2026, to stockholders who are on record as of March 31, 2026.

The announcement reflects Zimmer Biomet's unparalleled expertise, with over 90 years of experience in the medical technology field. The company operates across more than 25 countries and engages in sales across over 100 markets. Its comprehensive product portfolio is enhanced by integrated digital and robotic technologies designed to improve patient mobility, health, and overall clinical outcomes. By leveraging advanced data, analytics, and artificial intelligence, Zimmer Biomet is poised to evolve its offerings continually, meeting the growing demands of healthcare providers and patients in the orthopedic sector.

Zimmer Biomet's rich heritage is complemented by its focus on innovation and quality. The company’s progressive culture encourages the development of advanced solutions that streamline surgical processes and enhance operational efficiencies. By maximizing the effectiveness of its product lines and ongoing investments in research and development, Zimmer Biomet aims to solidify its leadership position in the medical technology industry, ensuring that it remains at the forefront as medical advancements continue to shift.

In addition to their dividend announcement, the company provides stakeholders access to detailed corporate information, including career opportunities and investor materials, on its website and social media platforms. This ongoing engagement underscores Zimmer Biomet’s transparency and desire to foster a strong connection with both investors and healthcare professionals.

Zimmer Biomet's commitment to returning capital to shareholders while embracing innovation positions the company well for future growth. As it maintains a focus on enhancing health outcomes through state-of-the-art technologies, the company's legacy of trusted leadership remains evident in its strategic initiatives aimed at improving patient care worldwide.